...
首页> 外文期刊>Breast cancer research and treatment. >The p160 ER co-regulators predict outcome in ER negative breast cancer.
【24h】

The p160 ER co-regulators predict outcome in ER negative breast cancer.

机译:P160 ER共调节剂预测ER阴性乳腺癌的结果。

获取原文
获取原文并翻译 | 示例

摘要

The SRC family of ER co-regulators are frequently overexpressed in breast cancer. Overexpression of AIB1 appears to be linked to hormone resistance in HER2 positive breast cancer. However, the role of these co-regulators in ER negative disease is poorly understood. SRC1, SRC2 and AIB1 expression was determined by immunohistochemical analysis of tissue microarrays constructed from tumours within the Edinburgh Breast Conservation Series (BCS). The BCS represents a fully documented consecutive cohort of 1,812 patients treated by breast conservation surgery in a single institution. Our results demonstrate tumours that overexpress both HER2 and AIB1 were associated with markedly reduced relapse free, distant relapse free and overall survival compared to HER2 and AIB1 only overexpressing tumours irrespective of ER status. In ER negative disease both SRC1 and AIB1 were linked to early relapse and death. The SRC family of ER co-regulators is involved in early relapse and resistance in both ER negative and ER positive breast cancer challenging the conventional concept that this effect is mediated solely via the ER.
机译:SRC系列ER共调节剂在乳腺癌中经常过表达。 AIB1的过度表达似乎与HER2阳性乳腺癌中的激素抗性有关。然而,这些共调节剂在ER阴性疾病中的作用是较差的。通过由爱丁堡乳房保护系列(BCS)内的肿瘤构建的组织微阵列的免疫组化分析来确定SRC1,SRC2和AIB1表达。该BCS代表了单一机构中乳房保护手术治疗的1,812名患者的完全记录的连续群组。我们的结果表明,与HER2和AIB1相比,与HER2和AIB1相比,过度减轻了HER2和AIB1的肿瘤与显着降低的复发,远处复发和整体存活率无关,而无论ER状态如何过度表达肿瘤。在ER阴性疾病中,SRC1和AIB1都与早期复发和死亡相关联。 ER共同调节剂的SRC系列参与早期复发和抗性,既有反常乳腺癌挑战,致常规概念,即这种效果仅通过ER介导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号